Interleukin (IL)-36a, IL-36b, and IL-36g are innate mediators of acute epithelial inflammation. We sought to demonstrate that these cytokines are also required for the pathogenesis of plaque psoriasis, a common and chronic skin disorder, caused by abnormal T helper 17 (T H 17) cell activation. To investigate this possibility, we first defined the genes that are induced by IL-36 cytokines in primary human keratinocytes. This enabled us to demonstrate a significant IL-36 signature among the transcripts that are up-regulated in plaque psoriasis and the susceptibility loci associated with the disease in genome-wide studies. Next, we investigated the impact of in vivo and ex vivo IL-36 receptor blockade using a neutralizing antibody or a recombinant antagonist. Both inhibitors had marked anti-inflammatory effects on psoriatic skin, demonstrated by statistically significant reductions in IL-17 expression, keratinocyte activation, and leukocyte infiltration. Finally, we explored the potential safety profile associated with IL-36 blockade by phenotyping 12 individuals carrying knockout mutations of the IL-36 receptor gene. We found that normal immune function was broadly preserved in these individuals, suggesting that IL-36 signaling inhibition would not substantially compromise host defenses. These observations, which integrate the results of transcriptomics and model system analysis, pave the way for early-stage clinical trials of IL-36 antagonists.
INTRODUCTION
Interleukin (IL)-36a, IL-36b, and IL-36g are a group of IL-1 family cytokines that signal through a common dimeric receptor, composed of the IL-36 receptor (IL-36R) and IL-1R accessory protein (IL-1RAcP) subunits. The activation of this complex triggers nuclear factor kB and mitogen-activated protein kinase (MAPK) signaling, leading to the production of proinflammatory molecules such as IL-1a/b, IL-6, and IL-8 (1) . Conversely, binding of IL-36R by the IL-36R antagonist (IL-36Ra) (encoded by the IL36RN gene) blocks downstream signal transduction (1) . The importance of this immunomodulatory mechanism was underscored by the discovery of loss-of-function IL36RN mutations in patients with generalized pustular psoriasis (GPP) (2) . This is a severe autoinflammatory disorder, which is characterized by recurrent episodes of neutrophilic skin pustulation and systemic inflammation (manifesting as an acute phase response with neutrophilia) (3) . Notably, most GPP patients also present with plaque psoriasis (hence, psoriasis), a chronic and disfiguring skin disease that affects 1 to 3% of the population (3) .
Research carried out in the last decade has demonstrated that the abnormal activation of T helper 17 (T H 17) lymphocytes is a major disease driver in psoriasis (4) . At the same time, several lines of evidence suggest that IL-36 cytokines are also likely to have a pathogenic role. First, individuals with GPP show elevated IL-36 expression in the skin (5) and present a risk of psoriasis that is 10 times higher than that observed in the general population (6) . Second, the gene encoding the IL-36R (IL1RL2) maps to a locus showing genome-wide significant association with psoriasis (7) . Finally, work carried out in animal models has demonstrated that IL-36 cytokines can activate dendritic cells and thus promote T H 17 lymphocyte polarization (8) . Because the IL-17 molecules released by T H 17 cells can, in turn, up-regulate IL-36 production, it has been proposed that the two cytokines drive a powerful feedback loop, which effectively propagates skin inflammation (9) . Together, the above observations suggest that germline IL36RN mutations cause widespread up-regulation of IL-36 signaling and severe autoinflammation (GPP), whereas localized, T H 17-dependent overexpression of IL-36 cytokines amplifies cutaneous immune responses in psoriasis. Thus, we propose that IL-36 is a shared disease driver, which contributes to the onset of plaque and pustular psoriasis through different molecular mechanisms.
Here, given that the role of IL-36 in GPP is well established, we have investigated IL-36 signaling as a pathogenic mediator and therapeutic target in psoriasis. By following up the results of IL-36 transcription profiling with targeted inhibition experiments, we demonstrated that in vivo and ex vivo IL-36 blockade can reverse the inflammatory phenotype of psoriasis skin lesions. We also showed that mutations that abolish IL-36 signaling do not substantially compromise human immune function, suggesting that pharmacological IL-36 blockade is likely to have an acceptable safety profile.
RESULTS
IL-36 signature genes are up-regulated in psoriatic skin lesions and enriched within psoriasis susceptibility loci To explore the role of IL-36 in psoriasis, we first assessed the presence of an IL-36 signature in the disease transcriptome. To date, IL-36 target genes have only been profiled in a single microarray study based on the stimulation of keratinocyte cultures with unprocessed IL-36 cytokines (10) . Because these precursor molecules were later found to have minimal biological activity (11), the power to detect differential expression was limited. Here, we sought to generate a reference IL-36 transcriptome through the RNA sequencing (RNA-seq) of healthy primary keratinocytes treated with bioactive IL-36a, IL-36b, or IL-36g (table S1) . The principal components analysis of our data set demonstrated a complete separation between treated (n = 3 for each cytokine) and untreated samples (n = 3) as well as an overlap between the profiles of keratinocytes stimulated with individual cytokines (Fig. 1A) . This pattern was confirmed by unsupervised hierarchical clustering (Fig. 1B) , suggesting important similarities between the three IL-36 transcriptomes.
We found that 4096, 4459, and 3468 genes were differentially expressed [false discovery rate (FDR), <0.05] upon treatment with IL-36a, IL-36b, and IL-36g, respectively (Fig. 1C ). Of these, 207, 352, and 229 were up-regulated by at least twofold ( Fig. 1C and table  S2 ). In keeping with the results of the principal components analysis and hierarchical clustering, we observed a substantial overlap between these data sets, with 182 genes (hereafter referred to as the IL36_182 set) induced by all three cytokines (Fig. 1C ). These included previously described IL-36-dependent loci (CCL20, CXCL1, IL8, DEFB4A, and STEAP4) (5, 10), as well as novel targets such as the chemotactic proteins S100A7, S100A8, and S100A9 and the phospholipase PLA2G4D, which generates the lipid antigens presented by Langerhans cells (Fig. 1C and table S2 ) (12) .
In keeping with the notion that IL-36 is a dominant cytokine in the GPP skin transcriptome, we found 58 IL36_182 genes among the 500 that were most significantly up-regulated in a recently described (5) GPP cohort (Fig. 1D) . We then reanalyzed a publicly available psoriasis data set (13) and found 68 IL36_182 loci among the 500 most overexpressed genes (Fig. 1D) . The overlap between the IL36_182 set and the genes up-regulated in psoriasis or GPP was highly significant (P < 10 −30 for both diseases), but the same did not apply to the gene set induced by IL-4 (P > 0.03 for both GPP and psoriasis), a T H 2 cytokine that was analyzed as a negative control ( fig. S1 ).
To complement the above observations, we also examined the overlap between IL-36 target genes and psoriasis susceptibility intervals previously detected in genome-wide association studies (GWAS). We found that the IL36_182 set was significantly enriched among the genes that lie within psoriasis-associated regions (P = 9.1 × 10
), but not among those that map to unrelated susceptibility loci, linked to autism or schizophrenia (P > 0.05 for both diseases) (Fig. 1E) . Thus, our analyses identified a clear IL-36 gene signature in GPP and psoriasis.
IL-36 signature genes cluster to pathways implicated in the pathogenesis of psoriasis To further explore the biological significance of our differential expression findings, we undertook a gene set enrichment analysis of the IL-36a, IL-36b, and IL-36g transcriptomes. This demonstrated a marked overrepresentation of inflammatory processes implicated in the pathogenesis of psoriasis. The pathway showing the most significant enrichment in our data set was "Role of IL-17A in psoriasis," with an FDR of <10 −10 observed for all three cytokines. In keeping with this result, a reanalysis of a published IL-17 transcriptome (14) revealed that 26 of 46 (56%) of the genes that are up-regulated by IL-17 in keratinocytes are part of the IL36_182 set (table S3) .
Very significant FDRs were also detected for pathways related to the infiltration of inflammatory elements into lesional skin ("Granulocyte adhesion and diapedesis" and "Agranulocyte adhesion and diapedesis;" FDR < 10 −6 for both) and the activation of p38 MAPK signaling (FDR ≤ 10 −5 ) ( Fig. 2A and table S4 ). There was a marked overlap between the processes driven by IL-36a, IL-36b, and IL-36g, with 45 pathways enriched in all three transcriptomes (P < 10 −30 for all pairwise comparisons) (Fig. 2B) .
We next extended our gene set enrichment analysis to the disease data sets. As expected, we found a substantial overlap between the pathways that were driven by IL-36 and those that were enriched in the GPP transcriptome (P = 9.4 × 10 −31 ) ( fig. S2 ). We then examined the psoriasis data set, where we identified 71 enriched pathways (FDR < 0.05), 37 (52%) of which were shared with the IL-36 transcriptome (P = 5.8 × 10 −35 ) (Fig. 2C and table S4 ). In keeping with the results of the differential expression analysis, we found that the genes underlying these enrichment signals were all part of the IL36_182 set (table S4) .
To validate the effects of IL-36 cytokines on genes that are relevant to the pathogenesis of psoriasis, we stimulated keratinocyte cultures obtained from additional healthy donors (n = 3). We focused our attention on a representative set of loci (highlighted in red font in Fig. 1C ) that were markedly up-regulated in psoriatic skin and mapped to pathways that were enriched in the disease transcriptome. These included IL36G, S100A7, and LCN2 ("Role of IL-17A signaling in psoriasis") and CCL20, IL8, and MMP9 ("Granulocyte/agranulocyte adhesion and diapedesis"), as well as IRAK2 and PLA2G4D ("p38 MAPK signaling"). Real-time PCR analyses confirmed that these genes were all strongly up-regulated by IL-36a, IL-36b, and IL-36g (Fig. 3A) . The induction was especially robust for S100A7 (all fold changes > 50) and IL36G (fold changes > 8.5). The latter result was also validated at the protein level (Fig. 3B) , suggesting the presence of a feedforward loop that sustains IL-36 expression in inflamed skin. These results indicate that IL-36 cytokines [produced upon infection or trauma ( fig. S3) ] amplify keratinocyte inflammatory responses by up-regulating their own expression and that of molecules which attract T H 17 cells (CCL20) and directly or indirectly potentiate IL-17 signaling (S100A7, LCN2, and PLA2G4D) ( fig. S4 ).
In vivo IL-36R blockade improves the phenotypic appearance of murine psoriasiform dermatitis Having demonstrated that IL-36 cytokines drive immune pathways that are critical to the pathogenesis of psoriasis, we proceeded to assess the anti-inflammatory effects of IL-36 signaling inhibition. We first investigated the potential of IL-36 blockade in imiquimod-induced psoriasiform dermatitis, an IL-17-mediated mouse model of the disease, which is widely used in preclinical studies (15, 16) . As expected, we found that imiquimod administration resulted in an inflammatory skin phenotype characterized by increased acanthosis (epidermal thickness) (Fig. 4, A and B) , abundant leukocyte infiltration (Fig. 4 , C and D), up-regulation of IL-17-producing T cells (Fig. 4E and fig.  S5 ), and IL-17 mRNA (Fig. 4F) . These pathological manifestations, however, were substantially mitigated by 48-hour pretreatment with an anti-IL-36R neutralizing antibody.
First, the mice that had received the IL-36R blocking antibody presented with less severe skin lesions compared to littermates treated with an immunoglobulin G2a (IgG2a) isotype control (Fig. 4A) . IL-36 inhibition was also associated with a~30% reduction in acanthosis, which was accompanied by a comparable decrease in scale thickness (Fig. 4A ). This was consistent with the observed up-regulation of Krt10 (a marker of keratinocyte terminal differentiation) and the reduced expression of Krt16 (a marker of keratinocyte hyperproliferation) (Fig. 4B) .
Second, flow cytometry analyses of skin cell suspensions demonstrated a substantial decrease in neutrophil infiltration in mice treated with the anti-IL-36R antibody (Fig. 4C ). These animals also showed a substantial decline in the number of gd T cells (Fig. 4D) , which was especially pronounced for the IL-17-producing subpopulation (Fig. 4E ). This decrease, which was mirrored by a reduced accumulation of IL-17 + ab T lymphocytes ( fig. S5 ), was especially noteworthy, given the key pathogenic role of IL-17 + gd T cells in imiquimodinduced dermatitis (17) .
Finally, and in keeping with the diminished infiltration of inflammatory elements, real-time PCR analysis of lesional skin showed reduced cytokine (Il36g, Il17a, Il22, Tnf, Csf2, and Csf3) and chemokine (Cxcl1, Cxcl2, and Cxcl5) expression in mice treated with the anti-IL-36R antibody (Fig. 4F) . Together, these results show that in vivo IL-36 signaling inhibition has powerful anti-inflammatory effects on psoriasiform dermatitis.
Ex vivo IL-36R blockade improves the inflammatory phenotype of human psoriasis skin
To further investigate the therapeutic potential of IL-36 blockade, we investigated a validated ex vivo model of human psoriasis, which is based on the short-term culture (24 hours) of paired skin biopsies, obtained from lesional and nonlesional skin of patients (18) . This system reflects the complexity of the disease and effectively recapitulates the pathogenic cross-talk between keratinocytes and immune cells. Here, real-time PCR analysis of cultures obtained from five independent patients confirmed the up-regulation of IL36G and IL17A in lesional skin (Fig. 5A) . Supplementation of the culture medium with recombinant IL-36Ra markedly reduced the overexpression of these cytokines, alongside that of chemokines such as IL8 and CCL20 (Fig. 5A ). The treatment also reduced the levels of KRT16 while increasing KRT10 expression (Fig. 5A ). Parallel ELISA measurements confirmed that IL-36Ra 
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Top IL-36 up-regulated genes in GPP transcriptome supplementation inhibited the release of IL-17 and IL-36g into the culture medium (Fig. 5B) , thus validating the gene expression results at the protein level. Finally, immunofluorescence microscopy demonstrated a highly significant (albeit not absolute) reduction in the number of T lymphocytes and dendritic cells in IL-36Ra-treated lesional skin (Fig. 5C ). Given the decreased expression of chemokines such as CCL20, this is likely to reflect a reduced retention of immune cells within the tissue.
To complement these findings, we sought to investigate the mechanisms underlying the effects of IL-36Ra on psoriatic lesions. We first examined the expression of the IL-36R gene (IL1RL2) in disease-relevant cell types. Although transcript levels were low in normal skin-resident T lymphocytes, in vitrodifferentiated macrophages, and in vitrodifferentiated dendritic cells, IL1RL2 was very strongly expressed in keratinocytes (Fig. 5D ). This suggests that IL-36Ra treatment mostly affects the latter cell type, where it inhibits IL-36R-dependent chemokine and cytokine production. To further explore this model, we examined the impact of IL-36Ra on MAPK signaling, one of the main mediators of IL-36-driven cytokine induction. We found that p38 phosphorylation, which was examined as a representative readout of MAPK activation on the basis of the results of pathway enrichment analysis, was markedly reduced in IL-36Ra-treated skin (Fig. 5E and fig.  S8 ). These experiments demonstrate that ex vivo IL-36 inhibition reduces cytokine expression and leukocyte infiltration in psoriatic skin lesions, most likely through an effect on keratinocyte MAPK signaling.
Phenotyping of individuals carrying IL1RL2 knockout mutations supports the safety of IL-36 signaling blockade
Having demonstrated the anti-inflammatory effects of IL-36 signaling inhibition in different experimental systems, we sought to establish whether pharmacological IL-36 blockade would compromise human immune function. We hypothesized that naturally occurring mutations in IL1RL2 (the gene encoding the IL-36 signaling receptor) would mimic the effects of IL-36 signaling blockade. We therefore proceeded to ascertain a sample of individuals with homozygous IL1RL2 loss-of-function alleles.
To maximize the likelihood of identifying subjects carrying IL1RL2 knockout mutations, we focused our attention on a population displaying high rates of parental relatedness. We therefore queried the exome profiles of 2162 unrelated British-Pakistani individuals recruited by Born in Bradford, a community-based project that aims to investigate health outcomes in Bradford, UK (19) . We found that 28 unrelated study participants (1.3%) harbored low-frequency homozygous changes in IL1RL2. Twelve of these individuals carried likely knockout mutations, that is, homozygous missense alleles classified as damaging by multiple algorithms (table S5) . Notably, the most prevalent change was a p. Ala471Thr substitution, found in 9 of 12 subjects and previously characterized in vitro as a deleterious allele (20) .
To investigate the impact of these damaging IL1RL2 changes on immune function, we first reviewed the medical records of the 12 individuals harboring deleterious homozygous mutations. One had always lived in the United Kingdom, whereas the other 11 had grown up in rural Pakistan and only left the country as young adults. We found that all were in good health, and none had suffered from cardiovascular disease, cancer, or immune-mediated conditions. None of the 12 subjects had a history of recurrent infections. Although IL-36 signaling has been implicated in host defense against Mycobacterium tuberculosis (21), none of the 12 individuals had contracted tuberculosis, a condition that is endemic in Pakistan (22) . All showed normal leukocyte counts (table S6) .
To further explore these findings, we recalled six subjects with deleterious IL1RL2 mutations, five of whom were p.Ala471Thr homozygotes (the sixth was homozygous for a p.Ile229Met deleterious change). In parallel, we also recruited four age-, sex-, and ethnicitymatched controls, who carried wild-type IL1RL2 sequences (Fig. 6, A  and B) . Clinical examination confirmed that none of the individuals with IL1RL2 mutations presented with anomalies of the skin, oral mucosa, or lymph nodes. Serology tests showed that total IgA, IgG, and IgM levels were normal. The same applied to Aspergillus IgG levels, which were investigated because IL-36 signaling has been implicated in the response to this particular pathogen (23) . Finally, we found that all individuals with IL1RL2 mutations had circulating antibodies against varicella zoster virus and tetanus toxoid, showing that they had mounted an adequate immune response after antigen exposure (table S7) .
To investigate in more detail the immune phenotype associated with deleterious IL1RL2 alleles, we obtained peripheral blood mononuclear Fig. 3 . IL-36 cytokines amplify immune responses implicated in psoriasis pathogenesis. (A) Validation of IL-36 responsiveness in genes that contribute to the pathogenesis of psoriasis. Primary keratinocytes from three independent healthy donors were treated with IL-36a, IL-36b, IL-36g, or vehicle (−). Gene expression was compared in treated versus untreated keratinocytes, using real-time PCR. Data for each individual donor were normalized to transcript levels in untreated cells and are presented as the mean ± SEM of measurements obtained in triplicate stimulations. (B) Effect of IL-36 cytokines on the secretion of IL-36g by keratinocytes. IL-36g release was quantified by enzyme-linked immunosorbent assay (ELISA) after the stimulation of primary keratinocytes with IL-36a, IL-36b, and IL-36g. Data for each individual donor are presented as the mean ± SEM. P values were calculated by Student's t test. *P < 0.05, **P < 0.01, ***P ≤ 0.001, ****P ≤ 0.0001. cells (PBMCs) from the six individuals with homozygous knockout mutations and the four control subjects. We first demonstrated that IL1RL2 and IL1RAP (the gene encoding the IL-36R co-receptor) are both expressed in these cells ( fig. S6) . Next, we stimulated PBMCs with a representative IL-36 cytokine (IL-36a). We found that this treatment failed to upregulate downstream gene expression in individuals with IL1RL2 knockout mutations (Fig. 6, C and D) , despite a normal response to a control stimulation with phorbol 12-myristate 13-acetate (PMA)/ionomycin (Fig. 6E) . This confirmed that the p.Ala471Thr and p.Ile229Met alleles abolish IL-36R activity and formally demonstrated that the individuals who harbor these mutations lack a functional IL-36R.
Next, we treated PBMCs with Infanrix, a vaccine mix conferring protection against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type B. We then measured the number of IL-17 + T lymphocytes so as to investigate the effect of IL1RL2 mutations on adaptive responses to bacterial and viral antigens. We found that the induction of T cell-mediated IL-17 production was comparable in individuals with knockout changes and control subjects (Fig. 6F) . We obtained similar results when we stimulated PBMCs with Candida albicans extracts, showing that the response to this fungal pathogen was also unaffected (Fig. 6F) . Finally, we treated PBMCs with polyinosinic: polycytidylic acid [poly(I:C)], a synthetic double-stranded RNA that has been reported to up-regulate IL-36g, suggesting an involvement of IL-36 cytokines in antiviral defenses (24) . Again, we found that the induction of antiviral (IFIT1 and RSAD2) and anti-inflammatory gene products (IL-8) was comparable in control and knockout cells (Fig. 6, G and H ). These observations demonstrate that normal immune function is largely preserved in the presence of IL1RL2 knockout mutations, suggesting that IL-36 blockade is likely to be well tolerated. . All data were normalized to the transcript levels observed in untreated mice and are presented as means ± SEM. P values were calculated with one-way analysis of variance (ANOVA) and Dunnett' s posttest. *P < 0.05, **P < 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
DISCUSSION
Here, we have investigated the IL-36 signaling pathway as a shared pathogenic driver for plaque and pustular psoriasis. We initially examined the genes that are up-regulated by IL-36 treatment in skin keratinocytes. This is the cell type where the expression of IL-36R is highest and the effects of its stimulation are likely to be most pronounced. Keratinocyte RNA-seq allowed us to define a robust IL-36 signature, which is readily detectable among the genes that are overexpressed in psoriasis and those that map to disease susceptibility intervals. Our pathway enrichment analyses support a pathogenic model whereby IL-36-dependent genes drive several interconnected feedback loops that potentiate IL-17 signaling and leukocyte chemotaxis IL-36 is initially produced upon exposure to viral infection (24) and skin trauma, two well-known triggers of psoriasis exacerbation (3). IL-36 cytokines can then induce the expression of IL36G in an autocrine and paracrine fashion. Our real-time PCR and ELISA data indicate that this is a very robust upregulation, which is likely to play an important role in the propagation of cutaneous inflammatory responses. The induction of IL36A and IL36B is much weaker (table S2) . This suggests a prominence of IL-36g in early disease pathogenesis that could potentially be exploited for targeted therapeutic intervention.
IL-36 cytokines also drive the production of molecules that attract neutrophils (for example, IL-8 and CXCL1), dendritic cells (for example, CCL20), and T lymphocytes (CXCL10 and CCL20) to sites of inflammation. The strongest effect was demonstrated for S100A7, a potent inducer of T cell chemotaxis (25) , which is up-regulated more than 100-fold by IL-36b and IL-36g. The expression of LCN2, a molecule promoting neutrophil activation and infiltration (26) , was also markedly increased by IL-36 treatment.
In parallel, we showed that IL-36 can up-regulate the PLA2G4D phospholipase. This enzyme, repeatedly found to be overexpressed in psoriasis (27) , generates lipid antigens for presentation to CD1a-reactive T lymphocytes (12) . Given that the activation of the latter cells results in the production of IL-17 and IL-22 (12), PLA2G4D induction is another mechanism whereby IL-36 potentiates T H 17 activity. It is also possible that PLA2G4D might, like other molecules that are chronically overexpressed in psoriatic skin (28) , be recognized as an autoantigen by human leukocyte antigen-restricted T cells.
This in silico-derived pathogenic model is in keeping with the experimental characterization of IL-36g and PLA2G4D as psoriasis biomarkers (27, 29) . It is also borne out by the PBMCs obtained from individuals with IL1RL2 knockout mutations (n = 6) and control (n = 4) subjects were treated for 7 hours with IL-36a. Cytokine production was determined by real-time PCR (C; data are presented as the mean of triplicate stimulations) and ELISA (D; data are presented as the mean of duplicate stimulations). KMutH, knockout mutation homozygotes; Ctr, controls. (E to H) PBMCs obtained from individuals with IL1RL2 knockout mutations and control subjects were treated with PMA/ionomycin (E), Infanrix 5-in-1 vaccine (F), and C. albicans extracts (F), or poly(I:C) (G and H). Gene expression was measured by real-time PCR (E and G; data are presented as the mean of triplicate stimulations), numbers of IL-17-secreting T cells were quantified by enzyme-linked immunospot (ELISPOT) (F; data are presented as the mean stimulation index observed in triplicate stimulations) (example photomicrographs are shown), and cytokine release was determined by ELISA (H; data are presented as the mean of duplicate stimulations). All P values were calculated by Student' s t test. **P < 0.01. ns, not significant. results of our ex vivo and in vivo studies, where IL-36 blockers reduced IL-17 and IL-36 expression in lesional skin while also decreasing chemokine induction and T cell infiltration.
The in vivo work was carried out in a single animal model (albeit a widely used one), where IL-36 signaling inhibition could not completely reverse the consequences of imiquimod administration. Although this is an important limitation, the anti-inflammatory effects of the treatment were supported by multiple experimental readouts and further validated by ex vivo studies of patients' skin, as recommended by the latest guidelines on the analysis of imiquimodinduced dermatitis (15) . In this context, the incomplete resolution of inflammation may simply reflect the short-term nature of the treatment (7 days for in vivo and 24 hours for ex vivo assays). Thus, the analysis of experimental systems enabling prolonged IL-36 blockade (for example, three-dimensional organotypic skin models) may be needed to fully validate the therapeutic potential of IL-36 antagonists.
Real-time PCR analysis of cells obtained from healthy donors showed that IL1RL2 levels were low in macrophages, dendritic cells, and skin-resident T lymphocytes. Although IL1RL2 transcripts were present in neutrophils, the significance of this observation is unclear, given that IL-36R surface expression is not detectable in these cells (30) . Thus, the anti-inflammatory effects of IL-36 blockade are likely mediated by a disruption of keratinocyte activation, resulting from the binding of IL-36Ra to an abundantly expressed receptor.
Having demonstrated the in vivo and ex vivo efficacy of IL-36 signaling inhibition, we sought to investigate its long-term effects on human immune function. We undertook the phenotyping of individuals carrying IL1RL2 knockout mutations, because the analysis of lossof-function alleles can generate invaluable insights into the effects of targeted pharmaceutical inhibition. For instance, the safety of cholesterollowering PCSK9 inhibitors was supported by the observation that PCSK9 mutations do not affect human health (31) .
Here, we identified 12 individuals harboring IL1RL2 knockout changes through an analysis of the Born in Bradford cohort (19) . Although all the mutations present in this relatively small data set were missense variants, pathogenicity predictions and IL-36 stimulations showed that these were deleterious alleles, which had a profound impact on receptor function. Conversely, clinical examinations did not uncover any evidence for impaired immune function.
Serology tests also failed to detect any anomalies. Of particular interest, Aspergillus IgG levels were unremarkable, responses to C. albicans stimulation were normal, and none of the individuals with IL1RL2 knockout mutations presented with candidiasis, even if IL-36 signaling has been implicated in antifungal defenses (23) . Although the size of our data set does not allow us to exclude the possibility that IL-36 inhibition may confer vulnerability to rare infections, the data presented here indicate that IL-36 blockade is broadly compatible with normal immune function.
Our observations have important translational implications. Although biologics targeting the IL-23/T H 17 axis (especially IL-17 blockers) have transformed the treatment of psoriasis (32) , disease management can still be problematic in real-world settings, where the response to existing cytokine blockers does not match the efficacy levels observed in clinical trials (33) . The efficiency of biologic therapies is even lower in pustular forms of psoriasis, where the need for an effective treatment is especially pressing (3) .
In this context, the findings obtained in our model systems support the development of IL-36 blockade as a therapeutic strategy for plaque and pustular psoriasis. Although the phenotyping of individuals harboring IL1RL2 knockout mutations suggests a favorable safety profile for IL-36 antagonists, we cannot exclude the possibility that these subjects may have developed compensatory immune mechanisms in early life. It is also possible that the effects of IL1RL2 mutations may have been mitigated by genetic modifiers occurring at high frequency within the British Pakistani population. In spite of these limitations, the immunocompromised phenotype of individuals suffering from other receptor deficiencies suggests that IL-36 signaling may indeed be dispensable to host defenses and warrants further characterization of IL-36 antagonists in phase 1 clinical trials.
MATERIALS AND METHODS

Study design
The aim of this study was to demonstrate that IL-36 cytokines play a pathogenic role in psoriasis and to validate the IL-36R as a therapeutic target. The first objective was pursued by demonstrating that IL-36-dependent genes identified in keratinocyte RNA-seq experiments were enriched in the psoriasis skin transcriptome and in disease-associated loci. The second objective was investigated in in vivo and ex vivo studies of IL-36R blockade. Deep phenotyping of individuals who lack a functional IL-36R owing to IL1RL2 knockout mutations was also undertaken to assess the long-term effects of IL-36 signaling inhibition.
The RNA-seq experiment was carried out in triplicate to maximize the power of detecting differentially expressed genes at a coverage exceeding 2 × 10 7 reads per sample (34) . In vivo studies were carried out in two groups of five mice on the basis of previous experience with comparable work (18) .
For the remaining experiments, sample sizes were dictated by the availability of psoriasis patients and IL1RL2 knockouts matching our strict inclusion criteria (see the Supplementary Materials). mRNA levels (see table S9 for details of real-time PCR primers), cytokine concentrations, and leukocyte numbers were investigated as predefined end points. Immunofluorescence and ELISPOT images were quantified in a blinded fashion. No randomization of animal groups was necessary. Although drug administration to imiquimod-treated mice was not blinded, epidermal and scale thickness measurements were assessed in a blinded fashion. Primary data are located in table S10. Details of sampling and experimental replicates are provided in each figure legend.
Human subjects
This study was performed in accordance with the Declaration of Helsinki and was approved by the National Research Ethics Service Committee London-Chelsea. Written informed consent was obtained from all participants. Adult patients with psoriasis (n = 10; table S8) were ascertained by dermatologists at Guy's and St. Thomas' NHS Foundation Trust (see the Supplementary Materials for further details). Discarded skin was obtained from four healthy donors undergoing plastic surgery at Guy's and St. Thomas' NHS Foundation Trust. Primary keratinocyte cultures were then established as described elsewhere (35) .
RNA sequencing
Sequences were aligned to the Ensembl Human GRCh37 transcriptome using Bowtie 2-2.2.2 (36) , and the number of reads that mapped to each gene was quantified with htseq-count (37) .
Raw expression data for psoriatic skin and the IL-4 and IL-17 keratinocyte transcriptomes were downloaded from the Gene Expression Omnibus database (GSE67785, GSE59275, and GSE12109, respectively), and differential expression was computed using DESeq2 (38) . Genes that were up-regulated by individual IL-36 cytokines (fold change ≥ 2, FDR < 0.05) were selected for pathway enrichment analysis, which was implemented with Ingenuity Pathway Analysis (Qiagen Bioinformatics).
In vivo IL-36 signaling blockade Mice were bred in the Francis Crick Institute animal facility under specific pathogen-free conditions, where experiments were performed in accordance with institutional guidelines and U.K. Home Office regulations. Female BALB/cJ mice (8 weeks old) treated for five consecutive days with 5% imiquimod (Meda AB) received daily intraperitoneal injections (150 mg) of anti-IL-36R antibody (M616, Amgen) or rat IgG2a isotype control (Bio X Cell), starting on day −2 of imiquimod administration. Full-thickness skin biopsies were collected on day 7 for histological staining, RNA extraction, and flow cytometry (see the Supplementary Materials for further details).
Statistical analyses
The significance of the overlap between the up-regulated genes (or enriched pathways) represented in Venn diagrams was calculated using the hypergeometric distribution (phyper function in R). Fisher's exact test was used to assess the enrichment of IL-36 signature genes within non-major histocompatibility complex intervals associated with psoriasis, schizophrenia, and autism. The NHGRI-EBI (National Human Genome Research Institute-European Bioinformatics Institute) Catalog of published GWAS (www.ebi.ac.uk/gwas; March 2017 update) was queried using the search terms "psoriasis," "schizophrenia," and "autism" to generate three lists of disease-associated single-nucleotide polymorphisms (SNPs). A window of ±50 kb was added to the lead SNP at each locus, and the genes mapping to the resulting regions were extracted using BioMart (www.ensembl.org/biomart).
Fisher's test and hypergeometric distribution P values were adjusted for multiple testing using the Bonferroni correction. Unless otherwise indicated, experimental data are presented as means ± SEM. Differences between groups were assessed using unpaired Student's t test or one-way ANOVA with Dunnett's posttest, as appropriate.
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